Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
BMC Infect Dis ; 24(1): 55, 2024 Jan 06.
Artigo em Inglês | MEDLINE | ID: mdl-38184533

RESUMO

BACKGROUND: The aim of the present study was to compare the epidemiological patterns of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infections, hospitalizations, deaths, and duration of hospitalization during the fourth, fifth and sixth epidemic waves of coronavirus disease 2019 (COVID-19) in Iran. METHODS: A multicenter retrospective observational study was conducted on hospitalized patients in four hospitals in the Babol district of northern Iran. The study periods were during the fourth, fifth, and sixth waves of the epidemic in Iran, (March 2021 to March 2022). A total of 13,312 patients with suspected COVID-19 were included. Patient demographics, medical history, length of hospital stay, and clinical outcomes were obtained from the hospital information system. Data on the cycle threshold (Ct) and SARS-CoV2 variant were collected for SARS-CoV2-positive cases. RESULTS: The highest number of hospitalized patients was reported during the fifth (Delta) wave (5231; 39.3%), while the lowest number of hospitalized patients was reported during the sixth (Omicron) wave (2143; 16.1%). In total, 6459 (48.5%) out of 13,312 hospitalized patients with suspected COVID-19 had a positive rRT-PCR result. The fifth (Delta) wave had the highest number of SARS-CoV2 rRT-PCR-positive hospitalized patients (3573, 55.3%), while the sixth (Omicron) wave had the lowest number (835, 12.9%). Moreover, 238 (3.7%) patients with laboratory-confirmed COVID-19 died. The hospital mortality rate was 6.8% in the fourth (Alpha) wave, which reduced to 2.7 and 3.5% in the fifth (Delta) and sixth (Omicron) waves, respectively (p < 0.001). CONCLUSIONS: This is the most comprehensive study evaluating the epidemiologic characteristics of laboratory-confirmed SARS-CoV2 cases in Iran during the Alpha, Delta, and Omicron waves. The highest number of SARS-CoV2-positive hospitalized patients was in the fifth wave of COVID-19 (dominance of the Delta variant), while the sixth wave (dominance of the Omicron variant) had the lowest number. Comorbidities were similar, and cardiovascular disease, diabetes, kidney disease, and hypertension were the main risk factors in all waves.


Assuntos
COVID-19 , SARS-CoV-2 , Humanos , RNA Viral , COVID-19/epidemiologia , Hospitalização , Hospitais
2.
Int J Clin Pract ; 2022: 1455708, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35685485

RESUMO

Objectives: To avoid worsening from mild, moderate, and severe diseases and to reduce mortality, it is necessary to identify the subpopulation that is more vulnerable to the development of COVID-19 unfavorable consequences. This study aims to investigate the demographic information, prevalence rates of common comorbidities among negative and positive real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) patients, and the association between SARS-CoV-2 cycle threshold (Ct) at hospital admission, demographic data, and outcomes of the patients in a large population in Northern Iran. Methods: This large retrospective cross-sectional study was performed from 7 March to 20 December 2020. Demographic data, including gender, age, underlying diseases, clinical outcomes, and Ct values, were obtained from 8,318 cases suspected of COVID-19, who were admitted to four teaching hospitals affiliated to Babol University of Medical Sciences (MUBABOL), in the north of Iran. Results: Since 7 March 2020, the data were collected from 8,318 cases suspected of COVID-19 (48.5% female and 51.5% male) with a mean age of 53 ± 25.3 years. Among 8,318 suspected COVID-19 patients, 3,250 (39.1%) had a positive rRT-PCR result; 1,632 (50.2%) patients were male and 335 (10.3%) patients died during their hospital stay. The distribution of positive rRT-PCR revealed that most patients (464 (75.7%)) had a Ct between 21 and 30 (Group B). Conclusion: Elderly patients, lower Ct, patients having at least one comorbidity, and male cases were significantly associated with increased risk for COVID-19-related mortality. Moreover, mortality was significantly higher in patients with diabetes, kidney disease, and respiratory disease.


Assuntos
COVID-19 , SARS-CoV-2 , Adulto , Idoso , COVID-19/epidemiologia , Estudos Transversais , Demografia , Feminino , Humanos , Irã (Geográfico)/epidemiologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Reação em Cadeia da Polimerase Via Transcriptase Reversa
3.
Caspian J Intern Med ; 13(Suppl 3): 244-253, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35872672

RESUMO

Background: The present study aimed to investigate the one-year prevalence of SARS-CoV-2, common comorbidities and demographic information among negative- and positive rRT-PCR in health care workers (HCW), hospitalized and outpatients. Also, the association between SARS-CoV-2 cycle threshold (Ct) and the outcomes of patients were analyzed in Babol, northern Iran. Methods: This large retrospective cross-sectional study was performed between March 2020 and March 2021. The records of 19232 hospitalized, outpatients and HCW suspected to COVID-19 were collected from teaching hospitals in the North of Iran. Results: Out of the 19232 suspected to COVID-19 patients, 7251 (37.7%) had a positive rRT-PCR result; 652 (9%), 4599 (63.4%) and 2000 (27.6%) of those were categorized as HCW, hospitalized and outpatients, respectively. Moreover, between the hospitalized and the outpatient group, 10.2 and 0.8% cases died, whereas no death cases were reported in the HCW. Furthermore, it seems that death rate was significantly different between the three groups of Ct value, the highest mortality in those with Ct between 21 and 30 (group B=7.6%) and the lowest in the group with the highest Ct (between 31 and 40 = 5.5%) (p<0.001). Conclusion: In summary, 37.7% of cases were positive for SARS-CoV-2; of which, 63.4, 27.6 and 9% were hospitalized, outpatients and HCW, respectively. With regard to the mortality rate in hospitalized patients and the significant association with Ct under 20 and 30, it seems that the early detection and the initial quantification of SARS-CoV-2 in the first week of the conflict and therapeutic considerations to reduce the relative load can reduce the mortality rate.

4.
Neuropharmacology ; 146: 117-127, 2019 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-30503994

RESUMO

Arbutin as a natural soluble glycosylated phenol possesses a wide range of pharmacological activities including anti-inflammatory and anti-oxidant effects. The present study was designed to evaluate the effect of arbutin supplementation on seizures behavior, memory performance, glial activation, release of inflammatory factors and neuroprotection in pentylenetetrazole-induced kindling model. Chemical kindling was induced by repetitive injections of PTZ at subconvulsive doses (36 mg/kg). Arbutin at doses of 25 or 50 mg/kg was administrated intraperitoneally (i.p.), 10 days before PTZ injection and its application was continued 1 h before each PTZ injection. High performance liquid chromatography (HPLC) analysis was performed to measure the arbutin content in hippocampus. After monitoring the behavioral signs of seizures, Morris water maze task was used to assess the spatial learning and memory of animals. Gene expression analysis was carried out to evaluate the effect of arbutin on expression of inflammatory mediators and astrocyte activation. Furthermore, immunostaining was used to assess the protein levels of astrocytes and neurons in hippocampus. The results of HPLC analysis showed that high amount of arbutin can be detected in hippocampus of arbutin + PTZ receiving animals. The seizure behavioral manifestations and memory dysfunction were reduced by arbutin in a dose-dependent manner. The mRNA levels of TNF-α, IL-6 and GFAP were significantly downregulated in animals treated by arbutin. Additionally, the levels of astrocytes activation and neuronal damage were attenuated in arbutin treated animals. These results suggest that arbutin attenuates glial activation, memory impairment and release of inflammatory mediators in model of chronic epilepsy.


Assuntos
Arbutina/farmacologia , Astrócitos/metabolismo , Disfunção Cognitiva/tratamento farmacológico , Citocinas/metabolismo , Epilepsia/tratamento farmacológico , Excitação Neurológica/efeitos dos fármacos , Animais , Antígenos Nucleares/metabolismo , Arbutina/análise , Modelos Animais de Doenças , Proteína Glial Fibrilar Ácida/metabolismo , Hipocampo/metabolismo , Interleucina-6/metabolismo , Masculino , Camundongos , Proteínas do Tecido Nervoso/metabolismo , Pentilenotetrazol/farmacologia , Convulsões/tratamento farmacológico , Aprendizagem Espacial/efeitos dos fármacos , Memória Espacial/efeitos dos fármacos , Fator de Necrose Tumoral alfa/metabolismo
5.
Int J Nanomedicine ; 14: 6481-6495, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31496698

RESUMO

BACKGROUND: Despite the numerous pharmacological activities of quercetin, its biomedical application has been hampered, because of poor water solubility and low oral bioavailability. In the present study, we fabricated a novel form of quercetin-conjugated Fe3O4-ß-cyclodextrin (ßCD) nanoparticles (NPs), and the effect of these prepared NPs was evaluated in a chronic model of epilepsy. METHODS: Quercetin-loaded NPs were prepared using an iron oxide core coated with ßCD and pluronic F68 polymer. The chronic model of epilepsy was developed by intraperitoneal injection of pentylenetetrazole (PTZ) at dose of 36.5 mg/kg every second day. Quercetin or its nanoformulation at doses of 25 or 50 mg/kg were administered intraperitoneally 10 days before PTZ injections and their applications continued 1 hour before each PTZ injection. Immunostaining was performed to evaluate the neuronal density and astrocyte activation of hippocampi. RESULTS: Our data showed successful fabrication of quercetin onto Fe3O4-ßCD NPs. In comparison to free quercetin, quercetin NPs markedly reduced seizure behavior, neuronal loss, and astrocyte activation in a PTZ-induced kindling model. CONCLUSION: Overall, quercetin-Fe3O4-ßCD NPs might be regarded as an ideal therapeutic approach in epilepsy disorder.


Assuntos
Epilepsia/tratamento farmacológico , Nanopartículas de Magnetita/química , Quercetina/uso terapêutico , beta-Ciclodextrinas/química , Animais , Astrócitos/efeitos dos fármacos , Modelos Animais de Doenças , Hipocampo/patologia , Excitação Neurológica , Nanopartículas de Magnetita/administração & dosagem , Nanopartículas de Magnetita/ultraestrutura , Masculino , Camundongos , Neurônios/efeitos dos fármacos , Neurônios/patologia , Pentilenotetrazol/administração & dosagem , Quercetina/farmacologia , Espectroscopia de Infravermelho com Transformada de Fourier
6.
Brain Res Bull ; 139: 190-196, 2018 05.
Artigo em Inglês | MEDLINE | ID: mdl-29522864

RESUMO

Nonylphenol (NP) has been introduced as the most common endocrine disturbing-chemical (EDC) in the environment. NP exerts several adverse effects on the reproductive system, immune system, and central nervous system (CNS) via its potent hormonal activity. In this study, the correlation between NP concentration and the resulting memory impairment and induction of anxiety was examined in adult rats. NP (at doses of 0.2 or 2 mg/kg) and corn oil (as NP vehicle) were orally administrated for 35 days. On day 36, animals were evaluated for anxiety and cognitive performance using elevated plus maze and Morris water maze test, respectively. Rats were sacrificed afterwards for serum, cerebrospinal fluid (CSF), amygdala, and hippocampus NP level measurement using high performance liquid chromatography (HPLC). The behavioral results indicated that NP exposure at the dose of 2 mg/kg significantly reduces spatial learning and memory. Additionally, anxiety-like behavior was increased in animals received NP exposure compared to the vehicle group. Analysis of HPLC results showed that high quantity of NP is accumulated in hippocampus and amygdala tissues. Regression analysis showed a significant linear correlation between NP concentration and behavioral impairment. Overall, these data demonstrate the significant relationship between NP concentration in particular brain regions and the behavioral deficit.


Assuntos
Ansiedade/induzido quimicamente , Encéfalo/metabolismo , Deficiências da Aprendizagem/induzido quimicamente , Fenóis/toxicidade , Análise de Variância , Animais , Ansiedade/patologia , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Química Encefálica , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Deficiências da Aprendizagem/patologia , Modelos Lineares , Locomoção/efeitos dos fármacos , Masculino , Aprendizagem em Labirinto/efeitos dos fármacos , Fenóis/metabolismo , Ratos , Ratos Wistar , Tempo de Reação/efeitos dos fármacos
7.
Neurosci Lett ; 674: 1-10, 2018 05 01.
Artigo em Inglês | MEDLINE | ID: mdl-29530814

RESUMO

Curcumin has been introduced as effective anti-inflammatory agent in treatment of several inflammatory disorders. Despite the wide range pharmacological activities, clinical application of curcumin is restricted mainly due to the low water solubility of this substance. More recently, we could remarkably improve the aqueous solubility of curcumin by its encapsulation in chitosan-alginate-sodium tripolyphosphate nanoparticles (CS-ALG-STPP NPs). In this study, the anti-inflammatory and myelin protective effects of curcumin-loaded NPs were evaluated in lysolecithin (LPC)-induced focal demyelination model. Pharmacokinetic of curcumin was assessed using high performance liquid chromatography (HPLC). Local demyelination was induced by injection of LPC into corpus callosum of rats. Animals were pre-treated with intraperitoneal (i.p.) injections of curcumin or curcumin-loaded NPs at dose of 12.5 mg/kg, 10 days prior to LPC injection and the injections were continued for 7 or 14 days post lesion. Hematoxylin and eosin (H&E) staining and immunostaining against activated glial cells including astrocytes and microglia were carried out for assessment of inflammation level in lesion site. Myelin specific staining was performed to evaluate the effect of curcumin-loaded NPs on myelination of LPC receiving animals. HPLC results showed the higher plasma concentration of curcumin after administration of NPs. Histological evaluation demonstrated that, the extent of demyelination areas was reduced in animals under treatment of curcumin-loaded NPs. Furthermore, treatment with curcumin-loaded NPs effectively attenuated glial activation and inflammation in LPC-induced demyelination model compared to curcumin receiving animals. Overall; these findings indicate that treatment with curcumin-loaded NPs preserve myelinated axons through amelioration of glial activation and inflammation in demyelination context.


Assuntos
Anti-Inflamatórios/administração & dosagem , Corpo Caloso/efeitos dos fármacos , Curcumina/administração & dosagem , Doenças Desmielinizantes/tratamento farmacológico , Bainha de Mielina/efeitos dos fármacos , Nanopartículas , Neuroglia/efeitos dos fármacos , Animais , Anti-Inflamatórios/farmacocinética , Corpo Caloso/patologia , Curcumina/farmacocinética , Doenças Desmielinizantes/induzido quimicamente , Modelos Animais de Doenças , Sistemas de Liberação de Medicamentos , Inflamação/induzido quimicamente , Lisofosfatidilcolinas/administração & dosagem , Masculino , Bainha de Mielina/patologia , Neuroglia/metabolismo , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA